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Abstract 
 
Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, incurable myopathy, linked to 
epigenetic de-repression of D4Z4 repeats on chromosome 4q, leading to ectopic DUX4 expression. 
FSHD patient myoblasts have defective myogenic differentiation, forming smaller myotubes with 
reduced myosin content. However, molecular mechanisms driving such disrupted myogenesis in FSHD 
are poorly understood. We performed high-throughput morphological analysis describing FSHD and 
control myogenesis, revealing altered myogenic differentiation results in hypotrophic myotubes. 
Employing polynomial models and an empirical Bayes approach, we established eight critical time-
points during which human healthy and FSHD myogenesis differ. RNA-sequencing at these eight nodal 
time-points in triplicate, provided temporal depth for a multivariate regression analysis, allowing 
assessment of interaction between progression of differentiation and FSHD disease status. Importantly, 
the unique size and structure of our data permitted identification of many novel FSHD 
pathomechanisms undetectable by previous approaches. Selected for further analysis here, were 
pathways that control mitochondria: of interest considering known alterations in mitochondrial 
structure and function in FSHD muscle, and sensitivity of FSHD cells to oxidative stress. Notably, we 
identified suppression of mitochondrial biogenesis, in particular via PGC1, the co-factor and activator 
of ERR. PGC1 knock-down caused hypotrophic myotubes to form from healthy myoblasts. Known 
ERR agonists and safe food supplements Biochanin A, Genistein or Daidzein, each rescued the 
hypotrophic FSHD myotube phenotype. Together our work describes transcriptomic changes in high 
resolution that occur during myogenesis in FSHD ex-vivo, identifying suppression of the PGC1-
ERR axis leading to perturbed myogenic differentiation, which can effectively be rescued by readily-
available food supplements. 
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Introduction 
 
Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent (12/100000 (1)) skeletal myopathy, 
for which there is currently no cure. The condition presents most notably as a descending skeletal 
muscle weakness and atrophy, beginning in facial muscles (such as the orbicularis oculi and orbicularis 
oris), and progressing to the biceps brachii and muscles of the shoulder girdle, before affecting specific 
lower limb muscles such as the tibialis anterior (2, 3). Interestingly, there is often a marked left-right 
asymmetry in the degree that muscles are affected. Curiously, muscles including the deltoids and 
quadriceps have less overt pathological damage until later in the disease process (2, 3). In addition to 
myopathy, FSHD is also associated with extra-muscular features including retinal telangiectasia and 
sensorineural hearing loss (4–6). FSHD is highly heterogeneous, with presentations varying 
dramatically between first degree relatives and even mono-zygotic twins (7, 8). Finally, there is a 
differential penetrance between males and females, with males typically presenting earlier in life (9). 
 
Genetically, FSHD is associated with loss of epigenetic repressive mechanisms including DNA 
methylation, histone modification and repressive chromatin proteins on an array of macrosatellite 
D4Z4 repeats in the subtelomere of chromosome 4q (3, 10). In 95% of cases (FSHD1 - MIM 158900), 
repeat-mediated epigenetic de-repression occurs due to contraction of this highly polymorphic region to 
between 1 and 10 D4Z4 repeats (11). In the majority of remaining cases (FSHD2 - MIM 158901), 
D4Z4 epigenetic de-repression is caused by mutation in the chromatin modifying gene SMCHD1, or in 
rare FSHD2 cases, by mutations in DNMT3B (12, 13). Each D4Z4 unit encodes an open reading frame 
for the double homeobox 4 (DUX4) retrogene. Thus, epigenetic de-repression allows transcription of 
DUX4 from the distal D4Z4 unit, which coupled with a permissive 4qA haplotype supplying a poly A 
signal, permits mis-expression of the homeodomain-containing DUX4 transcription factor (3, 11). 
DUX4 is normally expressed at the four-cell human embryo phase, where it activates a cleavage-stage 
transcriptional program (14, 15). However, when ectopically expressed in FSHD, DUX4 may drive 
pathology by direct induction of pro-apoptotic genes, coupled with interference of DUX4 with target 
gene activation of related transcription factors PAX3 and PAX7 (16, 17), which could affect satellite 
cell-derived myoblast function during any repair/regenerative response (18). 
 
Characterisation of FSHD patient-derived cells has revealed that FSHD myoblasts are sensitive to 
oxidative stress and differentiate into aberrant myotubes (16, 19). Indeed, amelioration of oxidative 
stress sensitivity in FSHD formed the basis of a recent clinical trial investigating the therapeutic 
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potential of a cocktail of nutritional supplement anti-oxidants (20, 21). This trial demonstrated an 
improvement in maximum voluntary contraction and endurance time limit of quadriceps, although 
showed no improvement in the 2 minute walk test (20). Such results motivate investigation of other 
supplements that can rapidly be translated to clinic. 
 
FSHD myotubes in vitro are reported to display two major phenotypes: described as being smaller than 
control myotubes with a thin, elongated morphology and labeled as an ‘atrophic’ phenotype, or 
myotubes of the same size as controls but displaying an unusual distribution of myonuclei and 
dysregulation of microtubule network, so categorized as having a ‘disorganised’ phenotype (19). Both 
phenotypes are currently assessed by manual inspection of immunolabelling and there is no 
quantitative methodology for determination of myotube size and morphology.  
 
Proteomic studies have shown that FSHD ‘atrophic’ myotubes suppress skeletal muscle myosin heavy 
chain (MyHC) isoforms, whilst the ‘disorganised’ phenotype shows dysregulation of microtubule 
network formation, but no aberration in myosin isoforms (22). Endogenous DUX4c is more abundant 
in disorganised FSHD myotubes, which can be rescued by silencing DUX4c, but not DUX4 (23). It can 
be argued that the ‘atrophic’ myotube phenotype may be the more important contributor to the muscle 
weakness observed in FSHD (22, 24). Therapies designed to ameliorate this phenotype could be 
considered likely to drive clinical improvement in patients. 
 
While the so called ‘atrophic’ phenotype can be induced by DUX4 (24), how this is achieved is 
unclear, and the already barely detectable levels of DUX4 in FSHD patient biopsies and 
primary/immortalised muscle cultures, mean that an anti-DUX4 therapy may be insufficient (25, 26). 
Moreover, it is important to note that whilst the term ‘atrophic’ has been used to describe the small 
myotubes derived from FSHD patient myoblasts, there has not been rigorous investigation as to 
whether they actually develop as a consequence of loss of volume from an initially larger myotube 
(atrophy), as opposed to reduced growth (hypotrophy) and failure to ever reach the size of control 
myotubes. This distinction is of importance when considering molecular pathogenesis and therapies. 
 
Understanding how to rescue perturbed myogenic differentiation and the small FSHD myotube 
phenotype requires a detailed understanding of the molecular changes that occur during FSHD 
myogenesis in adult: a highly complex and dynamic process involving coordinated expression of a vast 
number of genes (27). High frequency transcriptomic time course studies of healthy mouse and human 
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myogenesis have revealed the importance of mechanisms that would otherwise be overlooked using 
fewer timepoints (28, 29). However, such transcriptomic studies investigating FSHD myogenesis are 
limited, usually covering only the two time points of proliferation and terminal differentiation (30, 31). 
Though such studies identify important molecular mechanisms in FSHD, such as HIF1-mediated 
oxidative stress sensitivity (30), they are limited by lack of extensive temporal range. 
 
Here we present a dynamic analysis of FSHD and control myogenesis. By first developing a high-
throughput image analysis software, we defined a quantitative measure of the FSHD small myotube 
phenotype. From a panel of FSHD and control myoblast cell lines, three matched pairs for which the 
FSHD line was forming smaller myotubes were identified. We next characterised morphologically the 
most well controlled line by high-throughput imaging of myogenesis, generating 8640 images over 5 
days of differentiation in triplicate. Our imaging revealed perturbed myogenic differentiation resulting 
in small FSHD myotubes, which developed as a consequence of hypotrophy rather than atrophy. This 
FSHD cell line aligns and fuses more slowly than its control, allowing us to establish a set of 8 critical 
time points in the differentiation dynamics, at each of which we performed transcriptomic investigation 
using RNA-sequencing, generating a total of 90 samples.  
 
Multivariate regression analysis generated a comprehensive description of myogenesis in FSHD. Of 
many pathways perturbed, a clear failure was evident to activate key mediators of the mitochondrial 
biogenesis program during differentiation to generate hypotrophic FSHD myotubes. Most notably, 
oestrogen-related receptor  (ERR) and Peroxisome proliferator-activated receptor gamma 
coactivator 1- (PGC1), together with their target genes, were dynamically repressed during FSHD 
myogenesis.  
 
PGC1 is an essential co-factor for ERR, an orphan nuclear receptor which up-regulates a cascade of 
transcription, including its own expression, to drive multiple processes including mitochondrial 
biogenesis (32, 33). Our data indicates that suppression of PGC1 in FSHD dynamically precedes 
suppression of ERR and its target genes during differentiation into hypotrophic myotubes. Crucially, 
siRNA-mediated knock-down of PGC1 causes the hypotrophic myotube phenotype during 
differentiation of control, healthy myoblasts. Moreover, supplementation with Biochanin A, an 
isoflavone capable of increasing activity of ERR (34), can rescue the hypotrophic myotube phenotype 
induced by PGC1 knock-down. Finally, Biochanin A, as well as two similar isoflavones, Genistein 
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and Daidzein, can rescue myogenic differentiation in FSHD cell lines, resulting in augmented myotube 
size. 
 
 
Results 
 
Novel, high-throughput image analysis software identifies FSHD myoblast lines with a small 
myotube phenotype 
Myogenesis is often perturbed in FSHD, with myotube morphology variable between patient-derived 
differentiated myoblasts. Previous studies have categorized FSHD myotubes broadly into an ‘atrophic’ 
or ‘disorganised’ phenotype (19, 22). Here we focus on the small or ‘atrophic’ myotube phenotype, of 
likely relevance to FSHD pathology. We obtained six immortalised FSHD myoblast cell lines and 
matched controls and one primary FSHD line and matched control. Three of these FSHD cell lines: 54-
2, 54-12 and 54-A5, alongside matched control 54-6, were isolated from a biceps biopsy from a male 
mosaic FSHD patient  (26). These lines are isogenic with the exception of the D4Z4 repeat length, 
which has 3 repeats in the FSHD lines, but 11 units in the control (26). Three further FSHD cell lines 
isolated from biceps muscle biopsies were; 12Abic, 16Abic and 15Abic and sibling matched controls 
12Ubic, 16Ubic and 15Ubic (35). Primary lines were derived from a male FSHD patient (MD-FSHD) 
and a sex matched control (GE-CTRL). Cell lines are detailed in Table S1. 
 
These twelve cell lines were differentiated for 3 days in triplicate and immunolabelled for total MyHC 
using monoclonal antibody MF20. Images were processed using a novel image analysis software 
written using the EBImage package in R (36), to ascertain the MyHC+ve area per unit area (field) 
(Figure 1A, software provided as Supplementary File 1). The FSHD 54-12 cell line relative to control 
54-6, the FSHD 16Abic cell line relative to sibling control 16Ubic and the primary FSHD MD-FSHD 
cell line relative to control GE-CTRL clearly displayed a small myotube phenotype, defined as a 
reduced mean MyHC+ve area relative to matched control (Figure 1B and 1C). 54-12, 54-6, MD-
FSHD and GE-CTRL were derived from males whilst 16Abic and 16Ubic were derived from females; 
hence these cell lines also permit investigation of gender independent mechanisms of FSHD 
myogenesis. None of the FSHD cells lines analysed generated myotubes that were significantly bigger 
than their associated controls. 
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Dynamic morphometric analysis of FSHD myogenesis reveals a delay in myoblast alignment and 
fusion 
Myogenesis is a highly dynamic process involving sophisticated morphological changes culminating in 
cell alignment, fusion and myotube growth by both accretion of further nuclei and hypertrophy (37). 
The FSHD small myotube phenotype is currently defined by the appearance of thin terminally 
differentiated myotubes. However, it is unclear whether this is due to a defect in myotube growth, or 
whether other morphological processes are perturbed. 
 
To analyse morphological changes during FSHD small myotube formation compared to control 
myogenesis, we performed high density, time-lapse microscopy imaging in triplicate on the isogenic 
(bar D4Z4 unit length) control 54-6 and FSHD 54-12 cell clones over 5 days of differentiation. One 
10x phase contrast image was captured every 5 minutes over the process, generating a total of 8640 
images (Supplementary Video 1A and 1B). We next developed an image analysis software to 
quantify morphological characteristics of each image, in particular the mean eccentricity of the cells, 
which approximately corresponds to the elongation of cells (Figure 2A). This generated a time course 
quantification of morphological changes during myogenic differentiation and fusion into 
multinucleated myotubes, which was closely reproducible across triplicates.  
 
Control 54-6 and FSHD 54-12 followed a similar pattern of gross morphological changes, beginning 
with a rapid alignment phase (increasing eccentricity), followed by a cytoplasmic expansion during 
fusion, in which unfused cells were pushed off the plate, causing them to round up (decreasing 
eccentricity). Following this rapid phase of cytoplasmic expansion, the first visible myotubes appeared 
(increasing eccentricity, Figure 2B). Although the gross pattern of change was similar between FSHD 
and control lines, the rates at which they occurred were different. An empirical Bayes approach 
revealed significant differences occurred particularly during the early stages of myogenesis, before the 
second day of differentiation (Figure 2B). Alignment and cytoplasmic expansion phases both took 
longer and resulted in less extreme morphological changes in the FSHD line 54-12, as compared to the 
healthy line 54-6. Importantly, this imaging revealed that the small FSHD myotubes develop by failing 
to reach the area of control myotubes (hypotrophy) rather than losing area (atrophy). 
 
Dynamic transcriptomic analysis of FSHD myogenesis  
Having established dynamic morphological differences between FSHD hypotrophic and control 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy405/5194059 by U
niversity C
ollege London user on 04 January 2019
 8
myogenesis, we next investigated the dynamic transcriptomic changes that may be driving the 
hypotrophic myotube FSHD phenotype. FSHD and control myoblasts fuse at different rates, with most 
clear morphological differences occurring before 48 hours. Therefore, selection of time points for 
transcriptomic analysis was made to ensure that we were not simply comparing time in differentiation, 
but also stage of differentiation, so that we were investigating time points where morphological defects 
in FSHD myoblasts are most pronounced.  
 
Fitting polynomial curves to the average eccentricity time courses for each cell line enabled 
identification of 3 robust turning points in eccentricity for each cell line, occurring within the first 48 
hours of myogenesis. Examination of images corresponding to these turning points identified them as 
myoblast alignment, fusion and myotube growth (Figure S1). Importantly, these events are 
characterised by clear morphological features, making them readily identifiable in subsequent 
experiments.  
 
FSHD 54-12 and control 54-6 myoblasts were plated in triplicate and induced to differentiate. Samples 
were harvested for RNA-sequencing at 8 time points corresponding to: 0 mins (confluent proliferating 
myoblasts), 440 mins (7.3 hours, control 54-6 alignment), 530 mins (8.8 hours, FSHD 54-12 
alignment), 1355 mins (22.6 hours, control 54-6 initiation of fusion), 1505 mins (25.1 hours, FSHD 54-
12 initiation of fusion), 1860 mins (31 hours, control 54-6 myotube formation), 2165 mins (36.1 hours, 
FSHD 54-12 myotube formation) and 5040 mins (3.5 days, myotube maturation). Images were 
obtained at 10x magnification at each time point prior to harvesting, to confirm morphology matched 
that expected from high-throughput image analysis (Figure S2). RNA-sequencing methodology and 
pre-processing are described in the Methods.  
 
Hallmarks of adult FSHD myogenesis include suppression of mitochondrial biogenesis genes 
regulated by ERR and PGC1 
To assess differential expression, we employed a multivariate regression approach that exploits the 
temporal depth of our RNA-seq data set. Expression Ei of the ith gene was modelled as a linear 
combination of FSHD status (cell type) and myogenic differentiation time. An interaction term was 
also included to investigate how FSHD status affected the relationship between gene expression and 
myogenic differentiation time: 
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𝐸௜ ൌ 𝑎௜𝐹𝑆𝐻𝐷௦௧௔௧௨௦ ൅ 𝑏௜𝑇𝑖𝑚𝑒ௗ௜௙௙௘௥௘௡௧௜௔௧௜௢௡ ൅ 𝑐௜ሺ𝐹𝑆𝐻𝐷௦௧௔௧௨௦: 𝑇𝑖𝑚𝑒ௗ௜௙௙௘௥௘௡௧௜௔௧௜௢௡ሻ 
 
Coefficient ai achieves positive values for genes whose expression is elevated in the FSHD 54-12 cell 
line relative to control 54-6, and negative values for genes that are repressed in FSHD 54-12 versus 
control 54.6. Coefficient bi similarly achieves positive values on genes that increase their expression 
during myogenic differentiation and negative values on those that decrease. The interaction term co-
efficient ci achieves positive values on genes with expression values which increase more during 
differentiation in FSHD 54-12 cells than control 54-6 cells, and negative values on genes with 
expression values that decrease more during differentiation in FSHD 54-12 cells than control 54-6 
cells.  
 
As an example, the expression patterns of the genes with the largest ai, bi and ci are shown (Figure 3A). 
The gene with the largest ai coefficient is CDKN2A, which encodes two proteins p16, an INK4 cyclin 
dependent kinase inhibitor and p14arf, an activator of p53. Upregulation of CDKN2A in the FSHD 54-
12 cells is consistent with reduced proliferation and increased apoptosis observed in FSHD myoblasts 
(19, 38). The gene with the largest bi coefficient is MYOM2 an M-protein expressed in fast skeletal 
muscle. The gene with the largest ci co-efficient is DOC2B, a double C2 domain-containing protein 
with a known role in insulin sensitivity in skeletal muscle. 
 
For each coefficient, we considered the 500 genes with the most significantly positive coefficient 
values and the 500 genes with the most significantly negative values and ran a Gene Set Enrichment 
Analysis (GSEA) (39) independently on each gene set.  
 
For coefficient ai, genes associated with positive values are up-regulated in the FSHD cell line. These 
were highly enriched for a number of stem cell gene sets, in line with our recent work demonstrating 
that DUX4 induces a less differentiated transcriptome (38) (Table S2). Genes negatively associated 
with the FSHD cell line were highly enriched for multiple components of the Polycomb Repression 
Complex 2 (PRC2) and H3K27me3 (Table S3), suggesting that this mode of epigenetic repression is 
lost in FSHD: consistent with a number of studies by ourselves and others suggesting epigenetic de-
repression in FSHD (40–43).   
 
For coefficient bi, genes associated with positive values are those that increase during differentiation 
regardless of cell type. As anticipated, these included many troponins, actins and myosins. The most 
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significantly enriched gene set for these genes identified by GSEA was the 
HALLMARK_MYOGENESIS gene set (p=3x10-51, Table S4): a gene set collated by the Broad 
Institute (39) containing genes known to be associated with skeletal muscle myogenesis. Its strong 
enrichment here confirms our dataset of myogenic differentiation shows concordance with other studies  
(39). Genes associated with negative values of bi (i.e. those suppressed in myogenesis) were 
significantly enriched for proliferation gene sets and genes involved in promoting oligodendrocyte 
differentiation (Table S5). 
 
For coefficient ci, genes associated with positive values are those that are induced specifically in FSHD 
differentiation (Table S6). These genes were highly enriched for targets of LEF1, a downstream 
component of canonical Wnt/-catenin signalling which we and others identified as aberrantly active in 
FSHD muscle (5, 43, 44). Transcriptional targets of MYOD1 were also significantly enriched, 
indicating inappropriate activation of MYOD1 during myogenesis in the FSHD cell line, in line with 
previous findings (16, 45). 
 
Importantly, genes associated with negative values of the interaction term co-efficient ci are those 
repressed specifically in FSHD differentiation (Table S7). Here we see a strong and consistent 
enrichment for ERR transcriptional target genes, as well as mitochondrial genes, oxidative 
phosphorylation, the TCA cycle and PGC1 target genes (Figure 3B).  
 
Suppression of mitochondrial biogenesis genes regulated by ERR and PGC1 is a general 
feature of FSHD myogenesis 
Of the many pathways that we found perturbed during myogenesis in FSHD (Tables S2-7), we decided 
to focus on the ERR/PGC1pathway, of interest considering the sensitivity of FSHD cells to 
oxidative stress and know mitochondrial dysfunction (21, 45, 46)Further examination revealed that in 
addition to insufficient activation of PGC1ERR target genes, there was also significant suppression 
of ERR transcripts (encoded by ESRRA) in differentiating FSHD 54-12 myoblasts, beginning from 
around 24 hours of differentiation (Figure 3C). PGC1 transcripts (encoded by PPARGC1A) were 
significantly suppressed at all time points of differentiation in the 54-12 FSHD myoblasts compared to 
54-6 controls (Figure 3D). 
 
To validate our findings from the FSHD 54-12 myogenesis, further RNA-sequencing was performed on 
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FSHD myoblast cell lines 16Abic, 12ABic, 54-2 and 54-A5, alongside matched control lines 16Ubic, 
12UBic and 54-A10, in triplicate at 0 mins (confluent proliferating myoblasts) and 5040 mins (3.5 
days, mature myotubes) of differentiation. Of the comprehensive description of FSHD myogenesis 
revealed by our analysis of the transcriptomics data, we were particularly interested in the 500 genes 
with the most significant negative associations with the interaction term co-efficient ci. In line with the 
derivation of these genes as those insufficiently activated during FSHD myogenesis, we found that 
while they showed similar levels in FSHD 16Abic and control 16Ubic confluent myoblasts, the level of 
these genes was significantly lower in mature FSHD 16Abic myotubes, as compared to control 16Ubic 
myotubes (p=0.003, Figure 3E). We next evaluated expression of ERR and PGC1 transcripts in 
FSHD 16Abic, 12Abic, 54-2 and 54-A5 cell lines or control 16Ubic, 12Ubic, 54-A10 cell lines at 
myoblast and myotube stage. Consistent with our findings in the 54-12 and 54-6 cell lines, PGC1 was 
suppressed in both combined FSHD myoblasts (p=0.0033, Figure 3F) and myotubes (p=6.8x10-6, 
Figure 3F) relative to combined controls, whilst ERR was only suppressed in combined FSHD 
myotubes (p=0.00031, Figure 3G). 
 
Knock-down of PGC1 recreates the hypotrophic FSHD myotube phenotype in control 
myoblasts  
Our dynamic transcriptomic analysis implicates suppression of PGC1 leading to insufficient 
activation of ERR as a critical molecular mechanism underlying perturbed differentiation and the 
FSHD hypotrophic phenotype. Given this model, we next investigated whether suppression of PGC1 
can drive formation of a hypotrophic myotube phenotype in control myoblasts. 
 
Control 54-6 myoblasts were plated in triplicate and co-transfected with either 4 independent siRNAs 
against PGC1, or scrambled control siRNAs. Effective siRNA-mediated knock-down of PGC1 was 
confirmed by RT-qPCR (Figure 4A). Transfected cells were then induced to differentiate for three 
days, before fixation and immunolabelling for MyHC (Figure 4B). Cells were then imaged and 
MyHC+ve area quantified using our image analysis software (Figure 4C).  
 
Control 54-6 myoblasts transfected with siRNA against PGC1 and then subjected to a differentiation 
protocol had a significantly lower mean MyHC+ve area and displayed a hypotrophic myotube 
phenotype on day 3 of differentiation, as compared to controls transfected with scrambled siRNA 
(Figure 4B and 4C). This demonstrates that suppression of PGC1as observed in FSHD myoblasts, 
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is sufficient to cause a hypotrophic phenotype in control, healthy myoblasts. 
 
ERR agonist Biochanin A rescues the hypotrophic myotube phenotype caused by knock-down 
of PGC1 in control myoblasts  
PGC1 is a critical co-factor of ERR, an orphan nuclear receptor that orchestrates a transcriptomic 
program regulating mitochondrial biogenesis and other processes. As we observe insufficient activation 
of ERR and its related mitochondrial biogenesis associated target genes in FSHD myoblasts during 
differentiation into hypotrophic myotubes, it is likely that PGC1 is driving the hypotrophic myotube 
phenotype through an insufficient activation of ERR. We thus postulated that activation of ERR in a 
PGC1-independent manner might rescue the hypotrophic myotube phenotype caused by PGC1 
knock-down. 
  
Biochanin A is an isoflavone found in Red Clover extract and soy that binds and activates ERR 
directly (34) and has an excellent safety profile in clinical trials (47, 48). Administration of 10 M 
Biochanin A to the differentiation medium was sufficient to rescue to control levels the hypotrophic 
myotube phenotype induced by PGC1 knock-down in control 54-6 myoblasts (Figure 4B and 4C). 
Interestingly, Biochanin A had no effect on mean MyHC+ve area in myoblasts transfected with control 
scrambled siRNA, indicating that the capacity of Biochanin A to counter the hypotrophic myotube 
phenotype is specific to suppression of the PGC1ERR axis (Figure 4B and 4C). 
 
Biochanin A, Daidzein or Genistein rescue the hypotrophic myotube phenotype in FSHD  
We next investigated whether Biochanin A can reduce the hypotrophic myotube phenotype in FSHD 
myoblasts, where PGC1 is endogenously suppressed (Figure 3). We plated FSHD myoblasts that 
give hypotrophic myotubes, namely FSHD 54-12, 16Abic and MD-FSHD myoblasts alongside control 
54-6, 16Ubic and GE-CTRL myoblasts (Figure 1) and induced differentiation with/without 10 M 
Biochanin A. After 3 days, cells were fixed and immunolabelled for MyHC, images were acquired and 
analysed for MyHC+ve area (Figure 5A). To first check that Biochanin A was targeting ERR, RNA 
was isolated from FSHD 54-12 myotubes and RT-qPCR performed, which confirmed a significant 
mean 2.3 fold up-regulation of ERR (which auto-activates) in Biochanin A-treated samples (Figure 
5B). Biochanin A significantly increased mean MyHC+ve area of myotubes in all three FSHD cell 
lines (Figure 5C and 5D). However, Biochanin A had no effect on average MyHC+ve area in control 
54-6, 16Ubic and GE-CTRL myotubes (Figure 5C and 5D).  
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Daidzein and Genistein are also isoflavones that have similarly been demonstrated to activate ERR in 
vitro, although to lower levels than Biochanin A (34). We differentiated FSHD 54-12, 16Abic and MD-
FSHD myoblasts alongside control 54-6, 16Ubic and GE-CTRL with/without 10 M Daidzein or 10 
M Genistein. After 3 days, myotubes were fixed and immunolabelled for MyHC, images were 
acquired and analysed for MyHC+ve area (Figure 6A). Consistent with observations obtained with 
Biochanin A, Daidzein or Genistein both increased mean MyHC+ve area in the FSHD cell lines 
(Figure 6B and 6C). However, Daidzein or Genistein also acted to increase mean MyHC+ve area in 
control 54-6 and 16Ubic lines, but not in the primary control GE-CTRL (Figure 6B and 6C). Thus 
ERR agonists Biochanin A, Daidzein or Genistein can rescue the perturbed myogenesis that leads to 
formation of FSHD hypotrophic myotubes (summarized in Figure 7).  
 
Discussion 
 
Here we coupled high-throughput time course imaging and transcriptomics, generating over 8640 
images and 90 RNA-seq samples of healthy and FSHD myogenesis, to provide the first dynamic 
analysis of FSHD differentiation and myotube formation. Of the many transcriptional changes 
identified in this comprehensive description of myogenesis in FSHD, we concentrated on the finding 
that suppression of PGC1 leads to a dynamic repression of ERR from day 1 of differentiation, 
driving FSHD hypotrophic myotube formation. PGC1 knock-down is sufficient to create a 
hypotrophic myotube phenotype in control myoblasts. Importantly, FSHD myogenesis and hypotrophic 
myotubes can be rescued by administration of an ERR agonists Biochanin A, Daidzein or Genistein 
(Figure 7). 
 
A general caveat of this study is that the degree of myotube maturation attainable ex vivo is limited, so 
we are focusing on myogenic differentiation and the early phases of myotube maturation, but such 
stages are relevant for understanding the repair/regeneration response in FSHD, and for designing 
regenerative therapies. Our examination and measurement of myogenesis indicates that the term 
‘atrophic’ used to describe FSHD myotubes with a thin morphology (17) is misleading, as the 
myotubes do not appear to lose volume. Rather, these FSHD myotubes never attain the volume of 
controls, so a better description is a ‘hypotrophic’ phenotype, as adopted here. While selecting for 
FSHD lines that give hypotrophic myotubes may bias our analysis, a general reduction in muscle fibre 
cross sectional area is characteristic of FSHD muscle biopsies. Many muscle fibres clearly show an 
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atrophic phenotype (49). However, it can be argued that a failure of regenerating muscle fibres to reach 
the size of mature muscle fibres may also contribute to such muscle fibre size variability, which we can 
model using hypotrophic myotubes. 
 
PGC1 is a critical component of the mitochondrial biogenesis pathway which it initiates via ERR 
activation in two ways; firstly, it induces expression of ERR and secondly, it directly interacts with 
ERR to increase its ability to activate transcription, which is minimal in the absence of PGC1. 
Myoblasts isolated from FSHD patients display an oxidative stress sensitivity phenotype, and a number 
of molecular mechanisms have been proposed to underlie this, including over-activation of HIF1 
signalling (30, 43), glutathione redox pathway dysregulation (16) and importantly, mitochondrial 
dysfunction (21). Mitochondria in FSHD display aberrant ultrastructure and distribution within the 
myofibre, as well as defects in cytochrome c oxidase activity and ATP synthesis via the OXPHOS 
pathway (21). Moreover, these mitochondrial deficits correlate with functional muscle impairment in 
FSHD (21). A molecular understanding of mitochondrial dysfunction in FSHD remains elusive. 
However, it is likely that the suppression of PGC1 that we report here, could play a crucial role.  
 
FSHD patients also display a decreased ratio of reduced (GSH) to oxidized glutathione (GSSG), 
leading to a sensitivity to oxidative stress (21). PGC1 knockout causes a decrease of GSH, resulting 
in a reduced reactive oxygen species (ROS) detoxification (51). PGC1 is also directly involved in 
defense against oxidative stress by the up-regulation of antioxidant enzymes such as MnSOD, and 
increased levels of PGC1 have been shown to reduce damage attributed to ROS (52, 53). FSHD and 
DUX4 expressing myoblasts produce higher levels of ROS than matched controls (46), and such ROS 
accumulation may be attributable to mitochondrial dysfunction. Suppression of PGC1 in FSHD may 
inhibit the anti-oxidant response to this elevated ROS. Crucially, a key target gene of PGC1 is 
MnSOD, which is the only anti-oxidant enzyme not found up-regulated in FSHD muscle (21). 
 
In addition to up-regulation of mitochondrial biogenesis and suppression of oxidative stress, the 
PGC1/ERR complex also acts to induce angiogenesis by up-regulating VEGF in a HIF-1 
independent manner (54). This latter mechanism has been linked to poor/aberrant vascularisation of 
skeletal muscle and the retina when PGC1 is suppressed (54, 55). As well as muscle atrophy in 
FSHD, there are well reported vascular defects including retinal telangiectasia (4, 5), and a reduction in 
skeletal muscle capillary density (56). Both these vascular abnormalities could be explained by a 
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suppression of PGC1 in FSHD.  
 
Moreover, PGC1 suppression also results in a low grade inflammation and an up-regulation in serum 
TNF and IL6 (57). FSHD skeletal muscle has increased T-cell infiltration (58) and patients display 
elevated serum TNF in a manner that negatively correlates with muscle function (21). Lastly, PGC1 
suppression has been previously implicated in muscle atrophy, both during sarcopenia and in muscle 
wasting in chronic disease, whilst up-regulation of PGC1 has been associated with resistance to 
muscle atrophy (59, 60). 
 
PGC1 can be induced by a number of mechanisms, including cold temperature and exercise, both of 
which are mediated by 2-adrenergic activity (61). It is of note that five clinical trials have investigated 
2 agonists (albutamol/salbutamol) in FSHD. Though these trials did not report significant 
improvements in primary outcome measures and treated groups experienced adrenergic side effects, 
three of the trials reported improvements in secondary measures including lean body mass and muscle 
volume (62–66). We have shown that suppression of PGC1 may drive muscle hypotrophy in FSHD, it 
is possible that the reported increases in muscle mass under 2-adrenergic stimulation may be driven by 
up-regulation of PGC1.  
 
A more recent clinical trial has investigated the role of antioxidant dietary supplements in FSHD 
including vitamin C, vitamin E, selenium and zinc, which were well tolerated with no associated side 
effects (20). The study reported modest improvements in maximal voluntary contraction of quadriceps 
but no improvement in 2 minute walk test. Selection of supplements however, was not targeted to any 
particular molecular mechanism, and one may anticipate stronger results if this were the case. Here we 
have shown that safe ERR agonists Biochanin A, Daidzein or Genistein can rescue the hypotrophic 
myotube phenotype when FSHD myoblasts differentiate. Given the molecular motivation of these 
molecules and their safety profiles, they may be considered alongside anti-oxidants in future FSHD 
clinical studies. 
 
In summary, we have comprehensively described the morphological and allied transcriptional changes 
that occur during myogenesis in FSHD. Of particular note, such dynamic analysis of high-throughput 
data revealed that PGC1 suppression leading to ERR repression in FSHD contributes to perturbed 
myogenic differentiation and hypotrophic myotube formation. Moreover, modulation of the PGC1 - 
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ERR pathway by nutritional supplements such as Biochanin A, Daidzein or Genistein may prove a 
rapidly translatable therapeutic approach for improving muscle condition and repair/regeneration in 
FSHD patients. 
 
Methods 
 
Cell culture and myogenic differentiation 
Three immortalised FSHD human myoblast cell lines 54-12, 54-A5, 54-2 (3 D4Z4 units) together with 
two control lines 54-6 and 54-A10 (13 D4Z4 repeats), all from the biceps of a mosaic FSHD1 patient  
(26), were kind gifts from Dr Vincent Mouly of the Center for research in Myology, Paris. Six 
immortalised human myoblast lines from the biceps of 3 FSHD1 patients, 12Abic, 15Abic and 16Abic 
and 3 sibling matched controls 12Ubic, 15Ubic and 16Ubic (33), were kind gifts from Professor 
Charles Emerson from the UMMS Wellstone centre for FSHD. We isolated primary myoblast cell line 
MD-FSHD from the quadriceps of a 27 year old FSHD1 patient with 7 D4Z4 repeats, while control 
GE-CTRL was isolated from the quadriceps of an unrelated 48 year old male. Briefly, fresh biopsies 
were digested with Liberase™ TM (Research Grade) and cells amplified to around 10 million, before 
being immunolabelled using Mouse Anti-Human CD56 (Clone B159 - BD bioscience, CA, USA), then 
sorted via FACS (ARIA III) and further cultured to P5 (Table S1).  
 
Human myoblasts were cultured in Skeletal Muscle Cell Growth Medium (Promocell via VWR 
International Ltd, Leicestershire, UK) supplemented with 20% foetal bovine serum (ThermoFisher 
Scientific, MA, USA), 50 g/ml Fetuin (bovine), 10 ng/ml Epidermal Growth Factor (recombinant 
human), 1 ng/ml Basic Fibroblast Growth Factor (recombinant human), 10 g/ml Insulin (recombinant 
human), 0.4 g/ml Dexamethasone and 50 g/ml Gentamycin, at 37oC under 5% CO2. To induce 
differentiation, myoblasts were washed with PBS and placed in DMEM Glutamax (ThermoFisher 
Scientific, MA, USA) supplemented with 1/1000 recombinant bovine insulin (Sigma-Aldrich, Dorset, 
UK) and 1/1000 Gentamycin (ThermoFisher Scientific, MA, USA) at 37oC under 5% CO2. 10 M 
Biochanin A (Cayman Chemical Company, MI, USA), Genistein (FluoroChem, Derbyshire, UK) or 
Daidzein (Cayman Chemical Company, MI, USA) were added to the differentiation medium as 
indicated. Biochanin A stock solution was dissolved in water, so control samples were not 
supplemented with any excipient. Daidzein or Genistein stock solution was dissolved in DMSO and an 
equivalent concentration of DMSO was added to controls. Primary human myoblasts were treated with 
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all drugs dissolved in DMSO, and an equivalent concentration of DMSO added to controls. 
 
RNA-sequencing 
RNA-sequencing was performed on high quality (RIN > 8.0) DNA free RNA in three batches, a larger 
batch contained 48 samples describing in triplicate the control 54-6 and FSHD 54-12 cell lines at 8 
time points during differentiation: 0 mins (confluent proliferating myoblasts) 440 mins (control 54-6 
alignment), 530 mins (FSHD 54-12 alignment), 1355 mins (control 54-6 initiation of fusion), 1505 
mins (FSHD 54-12 initiation of fusion), 1860 mins (control 54-6 myotube formation), 2165 mins 
(FSHD 54-12 myotube formation) and 5040 mins (myotube maturation). A second batch was 
performed for validation and consisted of 24 samples describing in triplicate the 16Abic, 12Abic, 
16Ubic and 12Ubic cell lines at two time points: 0 mins (confluent proliferating myoblasts) and 5040 
mins (myotube maturation). A third batch was similarly performed for validation and consisted of 18 
samples describing in triplicate the 54-2, 54-A5, and 54-A10 cell lines at the same two time points in 
differentiation of 0 mins and 5040 mins. For all batches, 312,000 cells were plated in 12 well plates and 
incubated for 48 hours at 37oC and 5% CO2. The 0 mins sample was then harvested with cells in 
proliferation medium, before switching sister cultures to differentiation medium and harvesting after 
5040 mins. 
 
RNA was isolated using miRNeasy kit including DNase digestion (Qiagen, Manchester, UK) from 
each cell line at each time point in triplicate. RNA quality/concentration were checked by LabChip 
Bioanalyzer and Nanodrop and RNA-seq libraries were prepared using the Agilent sureselect stranded 
RNAseq protocol, which allows polyA selection but was modified to work with ribodepletion. 
Libraries were sequenced on an Illumina HiSeq2500. Raw reads were trimmed using trim-galore, 
utilising cutadapt14 (v0.4.0) to remove the Illumina Sequencing Adapter (AGATCGGAAGAGC) at 
the 3' end. Additionally, 12 bases were also trimmed from the 5' end of the reads since they showed a 
biased distribution. Reads were mapped to the human transcriptome using the human genome sequence 
GRCh38 and v82 gene annotations downloaded from Ensembl. Mapping was performed using tophat 
15 (v2.1.0) and bowtie 16 (v1.1.0), enabling the fr-firststrand option of tophat to restrict mapping to the 
sense strand of the transcript. Reads were assigned to genes using the featureCounts program 17 
(v1.5.0), counting fragments and ignoring multi-mapping reads, and restricted to the sense strand. The 
resulting matrix of read counts was analysed using R. RNA-seq data are available from the GEO data 
base (https://www.ncbi.nlm.nih.gov/geo/), accession numbers GSE XXXXXXXX. 
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Transcriptomic analysis 
The three batches were internally controlled and hence analysed separately as independent data sets. 
Each set was normalised using the DESeq package in R. Principal component analysis (PCA) revealed 
tight clustering of triplicates within each batch. For both data sets, the dominant principal component 
(PC1) associated with myogenic differentiation time and ordered samples by progression of 
differentiation, regardless of cell type. The second principal component (PC2) associated with FSHD 
status. Hence the two dominant components of variability of our data associate directly with the 
variables of interest. 
 
For the larger dataset a multivariate regression approach was employed to analyse how gene expression 
varied with myogenic differentiation and cell type, an interaction term was also included to determine 
how gene expression dynamics over differentiation time was influenced by cell type. The regression 
model for each gene i was as follows: 
 
𝐸௜ ൌ 𝑎௜𝐹𝑆𝐻𝐷௦௧௔௧௨௦ ൅ 𝑏௜𝑇𝑖𝑚𝑒ௗ௜௙௙௘௥௘௡௧௜௔௧௜௢௡ ൅ 𝑐௜ሺ𝐹𝑆𝐻𝐷௦௧௔௧௨௦: 𝑇𝑖𝑚𝑒ௗ௜௙௙௘௥௘௡௧௜௔௧௜௢௡ሻ 
 
For each gene the model was fit and the significance of the positivity or negativity of each co-efficient 
was determined at the 5% level. The genes corresponding to the top 500 positive and negative co-
efficient values were selected for GSEA, which was performed using a Fisher’s Exact test against the 
gene sets described by the Molecular Signatures Database (39). 
 
For evaluation of the expression of 500 genes found most significantly dynamically repressed in 
FSHD, we obtained the average of these genes in each sample corresponding to 16Abic and 16Ubic 
myoblasts and myotubes and performed a t-test to compare mean expression across samples, 
significance was assessed at the 5% level. For the evaluation of the expression of PPARGC1A and 
ESRRA gene expression in the FSHD myoblasts (54-2, 54-A4, 16Abic and 12Abic) alongside matched 
controls (54-A10, 16Ubic and 12Ubic), the normalized expression levels were z-normalised within 
patient-control group and an unpaired Wilcoxon test was employed to compare FSHD cell line 
expression to control, with significance assessed at the 5% level. 
 
Immunolabelling 
For immunolabelling, immortalized myoblasts were plated at 25,000 cells/well in 96 well plates and 
cultured for 48 hours in proliferation medium, while primary myoblasts were cultured for 24 hours, 
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before being switched to differentiation medium for 3 days. Cells were then fixed with 4% 
paraformaldehyde/PBS for 15 mins, washed thrice with PBS, then permeabilised with 0.1% Triton/PBS 
for 10 mins, washed thrice again with PBS then blocked in 10% goat serum (v/v) (DakoCytomation, 
Glostrup, Denmark) for 30 min before being incubated on a rocker overnight at 4oC with primary 
antibody against MyHC (MF-20, DSHB, IA, USA) at 1/400 in PBS supplemented with 1% goat 
serum). Cells were then washed thrice with PBS before being incubated at room temperature for 30 
min with AlexFluor conjugated secondary antibodies (eBioscience, Hertfordshire, UK) diluted 1:400 in 
PBS supplemented with 1% goat serum, washed thrice again with PBS and incubated at room 
temperature for 10 mins in 1:1000 DAPI (4’,6-diamidino-2-phenylindole)/PBS. Samples were imaged 
on a Zeiss Axiovert 200 M microscope using a Zeiss AxioCam HRm and AxioVision software version 
4.4 (Zeiss). At least 3 fields were taken at 100x magnification for each well, resulting in quantification 
of over 500 cells per well. 
 
Time course imaging 
Immortalised myoblast cell lines control 54-6 and FSHD 54-12 were plated in triplicate at confluency 
at the centre of a 96 well plate (25,000 cells per well) and induced to differentiate with a high volume 
of differentiation medium (350l/well to prevent medium evaporation during the 5 days of imaging). 
All remaining empty wells in the 96 well plate were filled with DMEM Glutamax to provide humidity 
to the culture chamber. Immediately after addition of differentiation medium cells, plates were placed 
into a Solent Scientific chamber at 37oC and 5% CO2. Cells were imaged using an Eclipse Ti-E Live 
Cell Imaging System by taking a 100x magnification, phase contrast image every 5 minutes from each 
well over a total of 5 days; this generated 1440 images per well per cell line, per repeat, resulting in a 
total of 8640 images. 
 
Image Analysis 
To analyse the images generated we wrote a high throughput image analysis software in R, using the 
EBImage package (36) (software provided as Supplementary File 1). The software can autonomously 
process hundreds of high quality, large images in the order of minutes. When analysing 
immunolabeling, each image is first split into 3 channels. For determination MyHC+ve area the 
channel displaying MyHC was passed through a low pass filter and to remove noise and binarise the 
image and a size filter was applied to remove background labelling, the positive proportion of the 
image was then quantified as MyHC+ve area (Figure 1A). The mean MyHC+ve area from 3 images 
per well was then used to calculate the mean±SEM MyHC+ve area for the triplicate wells for each cell 
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line, and areas tested against control using an unpaired two-tailed t-test. 
 
Image analysis software to interrogate the myogenesis time-course imaging data adapted the 
immunolabeling software. Each image taken in the time course was passed through a low pass filter to 
reduce noise and binarise the image, high intensity regions were filtered on size and morphology to 
remove objects not considered likely to correspond to cells and finally holes were filled in. The regions 
of high intensity following this thresholding typically corresponded to single cells. The eccentricity of 
each cell identified in each image by this thresholding was measured and the average eccentricity of the 
field was obtained for each 5 minute time point. We thus obtained a time course of eccentricities in 
triplicate for each cell line. The triplicates showed a similar pattern of changes that were distinct for 
each cell line. Differential eccentricities between cell lines were assessed by an empirical Bayes 
approach and p-value histograms confirmed that differential eccentricities were detectable between cell 
lines. Non-linear regression was used to fit polynomial curves to the mean (over the triplicates) 
eccentricity time course, for each cell line, the turning points of the curves were determined to assess 
the most extremely eccentric and non-eccentric time points for each cell line separately (Figure 2A). 
 
RT-qPCR 
Cells were plated in triplicate at 312,000 cells per well in 12 well plates, cultured for 48 hours and then 
switched to differentiation medium (treated with Biochanin A or following PGC1 siRNA-mediated 
knock-down) for three days before cells were harvested. RNA was isolated using miRNeasy kit 
(Qiagen, Manchester, UK) and reverse-transcribed using the Reverse Transcription Kit with genomic 
DNA wipeout (Qiagen, Manchester, UK); RT-qPCR was performed on a Viia7 qPCR system (Life 
Technologies) with MESA Blue qPCR MasterMix Plus and ROX reference dye (Eurogentec Ltd, 
Hampshire, UK) using TBP expression as a control. 
Primers used were as follows:  
ESRRA forward: 5’-AAGACAGCAGCCCCAGTGAA-3’ 
ESRRA reverse: 5’-ACACCCAGCACCAGCACCT-3’ 
PPARGC1A forward: 5’-GTGAAATTGAGGAGTGCACAGTAAA-3’ 
PPARGC1A reverse: 5’-TCACAGGTATAACGGTAGGTAATGAAA-3’ 
TBP forward: 5’-CGGCTGTTTAACTTCGCTTC-3’  
TBP reverse: 5’-CACACGCCAAGAAACAGTGA-3’ 
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siRNA Knock-down 
Cells were plated in triplicate at 80,000 cells per well in 6 well plates and incubated for 24 hours before 
each well was transfected. PGC1 mixed or control scrambled siRNA (Qiagen, Manchester, UK - 
Catalogue number 1027416). Solutions containing 1.5 l of either 4 mixed siRNAs (10 M) against 
PGC1 or control siRNA (10 M) and 150 l OptiMem and 9 l RNAiMax with 150 l OptiMem, 
were incubated at room temperature for 5 mins before mixing, then incubated at room temperature for a 
further 20 mins. Cells were then incubated in the mixture diluted at 1/8 in proliferation medium for 24 
hours at 37oC and 5% CO2, before trypsinisation and replating at a density of 25,000 cells per well in 
96 well plates. Cells were cultured for 2 days before switching to differentiation medium for 3 days 
followed by fixation and immunolabelling. 
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Figure Legends 
 
Figure 1: Automated Image analysis demonstrates that FSHD 54-12, 16Abic and MD-FSHD cells 
form smaller myotubes  
(A) Schema showing how image analysis software performs an automated image preprocessing of an 
MyHC immunolabelled image counterstained with DAPI and quantifies the MyHC+ve area. 
(B) Six FSHD myoblast cell lines (54-2, 54-A5, 54-12, 16Abic, 15Abic and 12Abic) and matched 
controls (54-6, 16Ubic, 15Ubic and 12Ubic) were plated in triplicate at 25,000 cells per well of a 96 
well plate and induced to differentiate for 3 days. Primary FSHD cells MD-FSHD and controls GE-
CTRL were similarly analysed. Following culture, myotubes were fixed and immunolabelled for 
MyHC and counterstained with DAPI to identify nuclei (Magnification: x100).  
(C) At least 3 fields were imaged per well and mean MyHC+ve area was quantified from 3 wells/line 
using the automated image analysis software. FSHD 54-12, 16Abic and MD-FSHD demonstrated 
significantly reduced mean MyHC+ve area relative to matched controls 54-6, 16Ubic and GE-CTRL 
respectively. Data is mean±SEM (n=3 wells per line), where an asterisk denotes significant difference 
between the MyHC+ve area in FSHD lines to matched controls (p<0.05) using an unpaired two-tailed 
t-test.  
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Figure 2: High-throughput time course imaging reveals morphological differences between 
myogenesis in FSHD and control myoblasts  
(A) Schema showing how image analysis software processes and quantifies the eccentricity/elongation 
of cells in a phase contrast image of differentiating myoblasts. 
(B) FSHD 54-12 and matched control 54-6 myoblasts were plated in triplicate in 96 well plates and 
induced to differentiate over 5 days. Cells were imaged every 5 minutes over the differentiation process 
and the images processed by our software. Mean eccentricities for each cell line are plotted and a 
polynomial curve of best fit is shown. An empirical Bayes approach was employed to ascertain time 
points that showed significant differences in eccentricities between FSHD 54-6 and control 54-12 cell 
lines. Thin vertical lines show time points which reached significance at the 5% level, and are coloured 
yellow to red in order of significance. Thick vertical green lines correspond to time points selected for 
investigation by RNA-sequencing. After day 3.5 (last vertical green line) myotubes began contracting 
and detaching from the plates.  
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Figure 3: Transcriptomic analysis of FSHD myogenesis reveals suppression of PGC1 and ERR  
(A) A multivariate regression model was fit to the time course RNA-seq data describing the control 54-
6 and FSHD 54-12 myoblasts during myogenesis. Co-efficient ai attains positive values if gene i is up-
regulated in FSHD myoblasts vs controls, and negative values if down-regulated. Co-efficient bi attains 
positive values if gene i is up-regulated in during myogenesis, and negative values if down-regulated. 
Co-efficient ci attains positive values if gene i is up-regulated during FSHD myogenesis but not in 
control myogenesis, and negative values if down-regulated. As an example, time course expression 
plots are shown for the genes with the highest co-efficient values for co-efficient ai, bi and ci, where 
thick lines represent mean expression across triplicates and thin lines denote maximum and minimum 
expression values observed across triplicates. 
(B) Bar plot displays log10 enrichment p-values for the top 5 enriched gene sets among the 500 genes 
with the most negative ci co-efficient (i.e. those suppressed in FSHD myogenesis). We see clear 
enrichment for target genes of ERR and genes involved in mitochondrial processes.  
(C) Expression of ESRRA (ERR) in FSHD 54-12 and matched control 54-6 myoblasts from RNA-seq 
analysis. Significant repression in FSHD myogenesis begins from day 1 of differentiation. Thick lines 
represent mean expression across triplicates and thin lines denote maximum and minimum expression 
values observed across triplicates. 
(D) Expression of PPARGC1A (PGC1) in FSHD 54-12 and matched control 54-6 myoblasts from 
RNA-seq analysis. Significant repression in FSHD myoblasts occurs at all time points analysed. Thick 
lines represent mean expression across triplicates and thin lines denote maximum and minimum 
expression values observed across triplicates. 
(E) The 500 genes with the most negative ci co-efficient (i.e. those suppressed in FSHD myogenesis) 
identified in the data set of the FSHD 54-12 and control 54-6 myoblasts were tested on RNA-Seq data 
from FSHD 16Abic and control 16Ubic at time 0 - confluent myoblasts (myob) and time 5040 mins - 
mature myotubes (Myot). Box-plots demonstrate that the mean expression of these 500 genes with the 
most negative ci co-efficient was also significantly lower in 16Abic FSHD myotubes vs 16Ubic control 
myotubes. The box represents the interquartile range (IQR), with the median indicated by a line. 
Whiskers denote min (1.5*IQR, max (observed value)); values were tested using an unpaired two-
tailed t-test.  
(F) Expression of PPARGC1A (PGC1) is suppressed in RNA-Seq from FSHD 16Abic, 12Abic, 54-2 
and 54-A5 cell lines at both time 0 - confluent myoblasts and time 5040 mins -mature myotube stage, 
compared to control 16Ubic, 12Ubic, 54-A10 cell lines. The box represents the interquartile range 
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(IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)); 
values were z-normalised within FSHD-control groups and tested using an unpaired Wilcoxon test. 
(G) Expression of ESRRA (ERR) is suppressed only in RNA-Seq from FSHD 16Abic, 12Abic, 54-2 
and 54-A5 cell lines at the time 5040 mins -mature myotube stage compared to control 16Ubic, 
12Ubic, 54-A10 cell lines. The box represents the interquartile range (IQR), with the median indicated 
by a line. Whiskers denote min (1.5*IQR, max (observed value)); values were z-normalised within 
FSHD-control groups and tested using an unpaired Wilcoxon test. 
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Figure 4: siRNA-mediated knock-down of PGC1 is sufficient to cause the hypotrophic FSHD 
myotube phenotype, which can be rescued by the ERR agonist Biochanin A. 
(A) RT-qPCR demonstrates that 4 combined siRNAs against PGC1 successfully suppresses PGC1 
(PPARGC1A) in control 54-6 myoblasts. Data expressed as meanSEM where an asterisk denotes 
significant difference (p<0.05) using an unpaired two-tailed t-test. 
(B) Control 54-6 myoblasts were transfected with a mixture of 4 siRNAs against PGC1 or a 
scrambled siRNA control and induced to differentiate for 3 days. Control 54-6 myoblasts were also 
transfected with combined siRNAs against PGC1 or a scrambled siRNA control but also exposed to 
10 M Biochanin A during 3 days of differentiation. Myotubes were then immunolabelled for MyHC 
and all nuclei counterstained with DAPI (Magnification: x100). 
(C) PGC1 knock-down significantly reduced MyHC+ve area. However, this reduction could be 
rescued to control levels by administration of 10 M Biochanin A to the differentiation medium. Data 
expressed as meanSEM (n=3 wells per line) where an asterisk denotes significant difference between 
the MyHC+ve area in control siRNA/untreated versus treated conditions (p<0.05) using an unpaired 
two-tailed t-test. 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy405/5194059 by U
niversity C
ollege London user on 04 January 2019
 37
 
 
 
 
 
 
 
 
 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy405/5194059 by U
niversity C
ollege London user on 04 January 2019
 38
Figure 5: ERR agonist Biochanin A rescues the FSHD hypotrophic myotube phenotype. 
(A) FSHD 54-12 and 16Abic myoblast lines and primary MD-FSHD alongside matched controls 54-6, 
16Ubic and GE-CTRL were induced to differentiate with/without 10 M Biochanin A for 3 days, fixed 
and immunolabelled for MyHC and nuclei counterstained with DAPI (Magnification: x100). 
(B) RT-qPCR demonstrates that 10 M Biochanin A significantly increases expression of ESRRA in 
FSHD 54-12 myotubes. Data expressed as meanSEM (n=3 wells per line) where an asterisk denotes 
significant difference (p<0.05) using an unpaired two-tailed t-test. 
(C and D) FSHD myoblast lines 54-12 and 16Abic and primary FSHD cells MD-FSHD alongside 
matched controls 54-6, 16Ubic and GE-CTRL were induced to differentiate with/without 10 M 
Biochanin A for 3 days, fixed, immunolabelled for MyHC and MyHC+ve area quantified. All 3 FSHD 
cell lines demonstrated increased MyHC+ve area with Biochanin A, whilst control myotubes were 
unaffected. Data expressed as meanSEM (n=3-5 wells per line), where an asterisk denotes significant 
difference between the MyHC+ve area in untreated versus Biochanin A treated myotubes (p<0.05) 
using an unpaired two-tailed t-test.  
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Figure 6: ERR agonists Daidzein or Genistein rescue the FSHD hypotrophic myotube 
phenotype. 
(A) FSHD myoblast lines 54-12 and 16Abic and primary FSHD cells MD-FSHD alongside matched 
controls 54-6, 16Ubic and GE-CTRL were induced to differentiate with/without 10 M Genistein or 10 
M Daidzein for 3 days, myotubes were then fixed, immunolabelled for MyHC and nuclei 
counterstained with DAPI (Magnification: x100).  
(B-C) Quantifying MyHC+ve area showed that Genistein or Daidzein increased MyHC+ area in 
myotubes of all FSHD cell lines, as well as in myotubes of the control 54-6 and 16Ubic lines, but not in 
primary control myotubes. Data expressed as meanSEM (n=3 wells per line) where an asterisk 
denotes significant difference from untreated (p<0.05) using an unpaired two-tailed t-test. 
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Figure 7: Suppression of PGC1/ERR expression in FSHD and rescue by ERR agonists  
Schematic summarising that PGC1/ERR suppression in FSHD drives an FSHD hypotrophic 
phenotype that can be rescued by ERR agonists Biochanin A, Daidzein or Genistein. Suppression of 
the ERR/PGC1 pathway in FSHD patients could also contribute to know features of FSHD 
pathology including oxidative stress sensitivity, aberrant vasculature and inflammation. 
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Supplementary Information Legends 
 
Supplementary File 1: Image analysis software 
R script for a shiny based user interface for the high-throughput image analysis software employed for 
processing and quantifying immunolabelling data. 
 
Supplementary Video 1: Videos of control 54-6 and FSHD 54-12 myoblasts differentiating over 5 
days. 
A) Representative video of control 54-6 myoblast differentiation 
B) Representative video of FSHD 54-12 myoblast differentiation 
 
Figure S1 - Images of control 54-6 and FSHD 54-12 myoblasts at the 8 time points selected for 
RNA-sequencing by consideration of eccentricity time-course of morphological changes. 
Images corresponding to each of the 8 time points selected from differentiating control 54-6 and FSHD 
54-12 myoblasts for transcriptomic analysis (Magnification: x100) are displayed alongside the time-
course of average eccentricity. 
 
Figure S2 – Images of control 54-6 and FSHD 54-12 myoblasts at time of harvesting for RNA-
sequencing 
Phase contrast images of control 54-6 and FSHD 54-12 myoblasts taken at time of harvesting the wells 
for RNA-sequencing, to confirm morphological staging matched that observed during the selection of 
the time points (Magnification: x100). 
 
Table S1: Description of cell lines analysed 
Cell line, FSHD status, Relationship to matched control cell line, Gender, Muscle Biopsied and 
Reference for the myoblast lines investigated. 
 
Table S2: GSEA results for genes up-regulated in FSHD 
GSEA results for the top 500 genes positively associated with the co-efficient ai in the multivariate 
analysis of the time-course RNA-seq data describing control 54-6 and FSHD 54-12 myoblast 
differentiation. These gene sets are up-regulated in FSHD. 
 
Table S3: GSEA results for genes down-regulated in FSHD 
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GSEA results for the top 500 genes negatively associated with the co-efficient ai in the multivariate 
analysis of the time-course RNA-seq data describing control 54-6 and FSHD 54-12 myoblast 
differentiation. These gene sets are down-regulated in FSHD. 
 
Table S4: GSEA results for genes up-regulated during myogenesis 
GSEA results for the top 500 genes positively associated with the co-efficient bi in the multivariate 
analysis of the time-course RNA-seq data describing control 54-6 and FSHD 54-12 myoblast 
differentiation. These gene sets are up-regulated during myogenesis. 
 
Table S5: GSEA results for genes down-regulated during myogenesis 
GSEA results for the top 500 genes negatively associated with the co-efficient bi in the multivariate 
analysis of the time-course RNA-seq data describing control 54-6 and FSHD 54-12 myoblast 
differentiation. These gene sets are down-regulated during myogenesis. 
 
Table S6: GSEA results for genes up-regulated during FSHD myogenesis 
GSEA results for the top 500 genes positively associated with the co-efficient ci in the multivariate 
analysis of the time-course RNA-seq data describing control 54-6 and FSHD 54-12 myoblast 
differentiation. These gene sets are up-regulated specifically during FSHD myogenesis. 
 
Table S7: GSEA results for genes down-regulated during FSHD myogenesis 
GSEA results for the top 500 genes negatively associated with the co-efficient ci in the multivariate 
analysis of the time-course RNA-seq data describing control 54-6 and FSHD 54-12 myoblast 
differentiation. These gene sets are down-regulated specifically during FSHD myogenesis. 
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Abbreviations 
FSHD - facioscapulohumeral muscular dystrophy 
DUX4 - double homeobox 4 
SMCHD1- structural maintenance of chromosomes flexible hinge domain containing 1 
DNMT3B - DNA methyltransferase 3 beta 
ERR - oestrogen-related receptor   
PGC1 - Peroxisome proliferator-activated receptor gamma coactivator 1- 
MyHC - myosin heavy chain 
DAPI - 4’ ,6-diamidino-2-phenylindole 
GSEA - Gene Set Enrichment Analysis  
PBS - phosphate buffered saline 
ROS - reactive oxygen species 
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